AZ, BMS, Lilly, Pfizer make investor's cut

Investor Osman Gulseven finds that of hundreds of healthcare companies listed on the New York Stock Exchange, only four fit his investment objective of  high profitability, substantial dividends and a maximum P/E ratio of 20. Each is a  large-cap drugmaker: AstraZeneca , Bristol-Myers Squibb, Eli Lilly & Co, and Pfizer. Article

Suggested Articles

Manufacturing

FDA warning letter slams Dollar Tree over its OTC drug suppliers

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

by Eric Palmer
shingrix
Vaccines

GSK's Shingrix supply will leap up, CEO says—in 2024, that is

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

by Eric Sagonowsky
Fujifilm Diosynth Biotechnologies in Texas
Manufacturing

Fujifilm investing $120M in U.S. gene therapy operations

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

by Eric Palmer